Status:

WITHDRAWN

Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)

Lead Sponsor:

University of Zurich

Conditions:

Nontraumatic Intracerebral Hemorrhage, Multiple Localized

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Intracerebral hemorrhage (ICH) is responsible for 10-15% of primary strokes. ICH is a dynamic process with three phases: initial hemorrhage, followed by hematoma expansion and perihematoma edema forma...

Detailed Description

After admission to the ICU the patients presenting with primary intracerebral hemorrhage (ICH) are evaluated for enrollment. If systolic blood pressure (SBP) is higher than 160 mmHg or SBP \<160 mmHg ...

Eligibility Criteria

Inclusion

  • Primary intracerebral hemorrhage (ICH)
  • Systolic blood pressure (SBP) \> 160 mmHg at screening
  • Systolic blood pressure (SBP) \<160 mmHg under intravenous antihypertensive drug (e.g. Urapidil), started less than 3 h before randomization
  • 18 to unlimited years of age
  • Signed informed consent obtained

Exclusion

  • Patients with secondary hemorrhage (bleeding source as aneurysm, arteriovenous malformation or traumatic)
  • Patients with concomitant severe critical illness (e.g. sepsis, multi-organ failure)
  • Positive pregnancy test for any female of childbearing potential or breast feeding female
  • Known allergy to any component of Clevidipine (Cleviprex®), Urapidil Ebrantil®), soya bean oil or severe egg protein allergy
  • Contraindications for Clevidipine (Cleviprex®): defect in the lipid metabolism, critical aortic stenosis
  • Contraindications for Urapidil (Ebrantil®): aortic coarctation, arterio-venous shunt, breastfeeding period
  • Patients with pre-existing disability and legal representative
  • Patients participating in a interventional clinical trial within the last 30 days before Start of Treatment

Key Trial Info

Start Date :

June 15 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 14 2021

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT03300479

Start Date

June 15 2017

End Date

May 14 2021

Last Update

November 8 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital Zurich

Zurich, Switzerland, 8091

Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®) | DecenTrialz